- Home
- HBB vs CERS Comparison
HBB vs CERS Comparison
Compare HBB & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- CERS
- Stock Information
- Founded
- HBB 1904
- CERS 1991
- Country
- HBB United States
- CERS United States
- Employees
- HBB N/A
- CERS N/A
- Industry
- HBB Home Furnishings
- CERS EDP Services
- Sector
- HBB Consumer Discretionary
- CERS Technology
- Exchange
- HBB Nasdaq
- CERS Nasdaq
- Market Cap
- HBB 292.6M
- CERS 324.3M
- IPO Year
- HBB 2017
- CERS 1997
- Fundamental
- Price
- HBB $19.27
- CERS $1.79
- Analyst Decision
- HBB
- CERS Buy
- Analyst Count
- HBB 0
- CERS 3
- Target Price
- HBB N/A
- CERS $3.17
- AVG Volume (30 Days)
- HBB 67.2K
- CERS 1.8M
- Earning Date
- HBB 10-30-2024
- CERS 10-30-2024
- Dividend Yield
- HBB 2.38%
- CERS N/A
- EPS Growth
- HBB 107.04
- CERS N/A
- EPS
- HBB 1.88
- CERS N/A
- Revenue
- HBB $647,834,000.00
- CERS $176,229,000.00
- Revenue This Year
- HBB $4.60
- CERS $26.47
- Revenue Next Year
- HBB N/A
- CERS $11.48
- P/E Ratio
- HBB $10.30
- CERS N/A
- Revenue Growth
- HBB 5.30
- CERS 14.71
- 52 Week Low
- HBB $13.92
- CERS $1.38
- 52 Week High
- HBB $31.78
- CERS $2.59
- Technical
- Relative Strength Index (RSI)
- HBB 26.27
- CERS 52.76
- Support Level
- HBB $20.03
- CERS $1.63
- Resistance Level
- HBB $21.02
- CERS $2.03
- Average True Range (ATR)
- HBB 1.04
- CERS 0.12
- MACD
- HBB -0.14
- CERS -0.00
- Stochastic Oscillator
- HBB 11.43
- CERS 52.94
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.